While early sales income wasn't meaningful, it was interesting to see interest earned for the qtr was $290,835 which is higher than the $204,252 admin and corporate costs for the quarter and offsets a significant part of total costs for the quarter. Quarter cash outflows were $1.173mill or $4.6mill annualised. The $32.8mill cash balance should easily suffice through FDA approval possibly late next year and the US sales rollout.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)